Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17586282 | 0.83 | CA2 (0.34) | — | |
| SCHEMBL16118625 | 0.80 | — | — | |
| SCHEMBL17586273 | 0.71 | EPHX2 (0.46) | DPP8DPP9 | |
| SCHEMBL23367156 | 0.70 | L3MBTL1 (0.31) | L3MBTL1 | |
| SCHEMBL17586289 | 0.69 | HPGDS (0.35) | — | |
| SCHEMBL13252955 | 0.68 | L3MBTL1 (0.33) | L3MBTL1 | |
| SCHEMBL8102998 | 0.68 | EPHX2 (0.59) | — | |
| SCHEMBL17586284 | 0.66 | GRIN2D (0.32) | — | |
| SCHEMBL18216823 | 0.65 | L3MBTL1 (0.34) | L3MBTL1 | |
| SCHEMBL18219780 | 0.65 | L3MBTL1 (0.34) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3193855-B1 | BICYCLIC COMPOUNDS | RECURIUM IP HOLDINGS LLC (US) | 2021-05-19 | — | — | EP | disclosed |
| US-10975035-B2 | Bicyclic compounds | RECURIUM IP HOLDINGS, LLC (US) | 2021-04-13 | — | — | US | disclosed |
| US-20190233377-A1 | BICYCLIC COMPOUNDS | Zeno Royalties & Milestones, LLC | 2019-08-01 | — | — | US | disclosed |
| US-10308609-B2 | Bicyclic compounds | Zeno Royalties & Milestones, LLC (US) | 2019-06-04 | — | — | US | disclosed |
| US-20160075654-A1 | BICYCLIC COMPOUNDS | RECURIUM IP HOLDINGS, LLC | 2016-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190233377-A1 | BICYCLIC COMPOUNDS | OPRK1, OPRM1, OPRL1 | DPP8 3251/4885DPP9 3684/4885L3MBTL1 4192/4885 |
| US-20160075654-A1 | BICYCLIC COMPOUNDS | OPRK1, OPRM1, OPRL1 | DPP8 3251/4885DPP9 3684/4885L3MBTL1 4192/4885 |
| US-10975035-B2 | Bicyclic compounds | OPRK1, OPRM1, OPRL1 | DPP8 3251/4885DPP9 3684/4885L3MBTL1 4192/4885 |
| US-10308609-B2 | Bicyclic compounds | OPRK1, OPRM1, OPRL1 | DPP8 3251/4885DPP9 3684/4885L3MBTL1 4192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.